What this study is
This phase I trial studies how well fluorine F 18 fluorthanatrace positron emission tomography (PET)/computed tomography (CT) works in patients with solid tumors. Fluorine F 18 fluorthanatrace is a radioactive tracer, a type of imaging agent that is labeled with a radioactive tag and injected into the body to help with imaging scans. PET/CT uses a scanner to make detailed, computerized pictures of areas inside the body. PET/CT with Fluorine F 18 fluorthanatrace may allow more tumor cells to be found in patients with ovarian, fallopian tube, or primary peritoneal cancer.
What's being tested
- Computed Tomography
Intervention · PROCEDURE
- Computed Tomography
Intervention · PROCEDURE
- Fludeoxyglucose F-18
Intervention · RADIATION
- Fluorine F 18 Fluorthanatrace
Intervention · RADIATION
- Positron Emission Tomography
Intervention · PROCEDURE
- Positron Emission Tomography
Intervention · PROCEDURE
Both Computed Tomography and Positron Emission Tomography
Undergo FDG PET/CT
Both Computed Tomography and Positron Emission Tomography
Undergo [18F]FTT PET/CT
Both Fludeoxyglucose F-18 and Fluorine F 18 Fluorthanatrace
Given IV
Study details
- Official title
- Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CT
- Sponsor
- M.D. Anderson Cancer Center
- Conditions
- Breast Carcinoma · Fallopian Tube Carcinoma · Ovarian Carcinoma · Primary Peritoneal Carcinoma · Recurrent Fallopian Tube Carcinoma · Recurrent Ovarian Carcinoma · Recurrent Primary Peritoneal Carcinoma · Solid Neoplasm
- Enrolling
- 300 people
- Starts
- 2018-12-18
- Est. completion
- 2027-06-30
- Design
- Open-label, single group, Phase 1
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex FEMALEHealthy volunteers Not acceptedYou may qualify if
- History of known or suspected solid tumor.
- At least one lesion ≥ 1.0 cm that is seen on standard imaging (e.g. computed tomography [CT], magnetic resonance imaging [MRI], ultrasound, fludeoxyglucose [FDG] PET/CT).
You can't join if
- Females who are pregnant or breast feeding at the time of screening will not be eligible for this study; a urine pregnancy test will be performed in women of child-bearing potential < 2 weeks prior to screening as standard of care.
- Inability to tolerate imaging procedures in the opinion of an investigator or treating physician.
- Any current medical condition, illness, or disorder as assessed by medical record review and/or self-reported that is considered by a physician investigator to be a condition that could compromise participant safety or successful participation in the study.
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (1)
1 openM D Anderson Cancer Center
Houston, Texas, United States
- Lilie L. Lin, MD · Contact713-563-2300lllin@mdanderson.org
- Lilie L. Lin, MD · Principal investigator
Recruiting
Study team
Sponsor
M.D. Anderson Cancer Center
Study ID 2017-0319
Principal investigator
Lilie L Lin
M.D. Anderson Cancer Center
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.